Nautilus Biotechnology Inc
NASDAQ:NAUT
Nautilus Biotechnology Inc
Nautilus Biotechnology, Inc. operates as a life sciences company. The company is headquartered in Seattle, Washington and currently employs 113 full-time employees. The company went IPO on 2020-08-07. The firm is engaged in creating a platform technology for quantifying and unlocking the complexity of the human proteome. The firm focused on transforming the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. Its platform end-to-end solution comprised of the proteome analysis system, consumables, and software. The firm is developing a prototype of a single-molecule instrument, Proteomic Analysis System. The Company’s Proteomic Analysis Platform leverages a nanofabricated, single-molecule protein array, multi-cycle imaging, and machine learning analysis to identify and measure the proteome with sensitivity and scale.
Nautilus Biotechnology, Inc. operates as a life sciences company. The company is headquartered in Seattle, Washington and currently employs 113 full-time employees. The company went IPO on 2020-08-07. The firm is engaged in creating a platform technology for quantifying and unlocking the complexity of the human proteome. The firm focused on transforming the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. Its platform end-to-end solution comprised of the proteome analysis system, consumables, and software. The firm is developing a prototype of a single-molecule instrument, Proteomic Analysis System. The Company’s Proteomic Analysis Platform leverages a nanofabricated, single-molecule protein array, multi-cycle imaging, and machine learning analysis to identify and measure the proteome with sensitivity and scale.
OpEx Down: Nautilus cut total operating expenses by 19% YoY in Q3 2025, showing strong cost control and focus on efficiency.
Cash Runway: The company ended Q3 with $168.5 million in cash, projecting runway through 2027.
Commercial Path: Early access for the Tau proteoform assay will launch in the first half of 2026, with broadscale capability launch planned for late 2026.
Research Momentum: Nautilus expanded collaborations with leading institutes (Buck, Allen, Mount Sinai) and will showcase the first externally generated Tau data at the World HUPO conference.
Market Validation: Extensive customer research found strong willingness to pay a premium for Nautilus’ differentiated platform.
Limited Near-term Revenue: Management expects limited revenue from initial early access programs, with meaningful revenue not expected until after 2026.
